In a more recent retrospective case–control analysis of patients with ovarian cancer enrolled on the ARIEL2 and ARIEL3 ovarian cancer studies, pre-existing TP53 CH mutations were found to be significantly associated with the development of therapy-related myeloid neoplasms after exposure to rucaparib [239]. The gene discussed is C4B; the disease is myeloid neoplasm.